Sciele Pharma

                   

Catalent Receives Outsourcing Award

packagingessentials.com
19-Nov-2008
        

Source: Catalent Pharma Solutions, 2008-Nov-18 Catalent Pharma Solutions, a leading provider of outsourced clinical and commercial packaging services to the global pharmaceutical and biotechnology industry, announced that they...

add comment
                   

Shionogi and Sciele Announce Successful Tender Offer and Commencement of Subsequent Offering...

yahoo.com
10-Nov-2008 2 related
        

ATLANTA & OSAKA, Japan----On October 6, 2008, Shionogi & Co., Ltd. and Sciele Pharma, Inc. announced the successful completion of the tender offer by Shionogi’s indirect wholly owned subsidiary, Tall Bridge, Inc. , to acquire...

add comment

SCIELE PHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in...

yahoo.com
10-Nov-2008 6 related
        

| Request a Trial to NEW EDGAR Online Pro Form 8-K for SCIELE PHARMA, INC. Entry into a Material Definitive Agreement, Change in Directors or Principal Item 1.01 Entry into a Material Definitive Agreement. Merger Agreement On...

add comment
                   

Sciele Completes Pivotal Phase III Program for Glycopyrrolate in Pediatric Patients with Chronic,...

yahoo.com
10-Nov-2008 1 related
        

ATLANTA----Sciele Pharma, Inc. today announced the completion of a pivotal Phase III program to support an NDA filing for glycopyrrolate liquid. Glycopyrrolate is being studied for use by pediatric patients with chronic,...

add comment
                   

Sciele Pharma Announces That Plethora Solutions Has Completed European Phase III Trial of PSD502...

yahoo.com
10-Nov-2008
        

ATLANTA----Sciele Pharma, Inc. , a specialty pharmaceutical company, today announced that Plethora Solutions Holdings PLC , the specialist developer of products for the treatment and management of urological disorders, has...

add comment

Sciele Pharma, Inc. Gives Notice of Anticipated Effective Date of Make-Whole Fundamental Change...

yahoo.com
10-Nov-2008
        

ATLANTA----Sciele Pharma, Inc. , today announced that, pursuant to the terms of the indenture relating to its 2.625% Contingent Convertible Senior Notes Due 2027 , it has designated October 8, 2008, as the "anticipated...

add comment
                   

Sciele Pharma and Addrenex Pharmaceuticals Announce Positive Phase III Clinical Results of...

yahoo.com
10-Nov-2008
        

ATLANTA----Sciele Pharma, Inc. and Addrenex Pharmaceuticals today announced that the preliminary analysis of the Phase III clinical study investigating the use of Clonicel® for the treatment of Attention Deficit Hyperactivity...

add comment
                   

Sciele Pharma and Plethora Solutions Announce Positive Phase III Clinical Results of PSD502 for...

pharmiweb.co.uk
07-Nov-2008 3 related
        

ATLANTA & LONDON--(BUSINESS WIRE)--Nov 7, 2008 - Well tolerated and devoid of systemic side effects Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Holdings PLC ("Plethora"-AIM:PLE), the specialist developer of...

add comment